2020
Adult diffuse glioma GWAS by molecular subtype identifies variants in D2HGDH and FAM20C
Eckel-Passow J, Drucker K, Kollmeyer T, Kosel M, Decker P, Molinaro A, Rice T, Praska C, Clark L, Caron A, Abyzov A, Batzler A, Song J, Pekmezci M, Hansen H, McCoy L, Bracci P, Wiemels J, Wiencke J, Francis S, Burns T, Giannini C, Lachance D, Wrensch M, Jenkins R. Adult diffuse glioma GWAS by molecular subtype identifies variants in D2HGDH and FAM20C. Neuro-Oncology 2020, 22: 1602-1613. PMID: 32386320, PMCID: PMC7690366, DOI: 10.1093/neuonc/noaa117.Peer-Reviewed Original ResearchConceptsGenome-wide association studiesGenome-wide p-value thresholdGlioma genome-wide association studiesElongation helicase 1Germline variantsChromosome 2Helicase 1Identifies variantsChromosome 7Association studiesChromosome 20Molecular subtypesMutationsGlioma molecular subtypesWild-type gliomasFAM20CDehydrogenase mutationsP-value thresholdPromoter mutationsAssociation of variantsIsocitrate dehydrogenase (IDH) mutationD2HGDHTelomerase reverse transcriptase (TERT) promoter mutationsNew regionsVariants
2019
Combining copy number, methylation markers, and mutations as a panel for endometrial cancer detection via intravaginal tampon collection
Sangtani A, Wang C, Weaver A, Hoppman N, Kerr S, Abyzov A, Shridhar V, Staub J, Kocher J, Voss J, Podratz K, Wentzensen N, Kisiel J, Sherman M, Bakkum-Gamez J. Combining copy number, methylation markers, and mutations as a panel for endometrial cancer detection via intravaginal tampon collection. Gynecologic Oncology 2019, 156: 387-392. PMID: 31787246, PMCID: PMC7018609, DOI: 10.1016/j.ygyno.2019.11.028.Peer-Reviewed Original Research
2017
Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials
Le-Rademacher J, Kanwar R, Seisler D, Pachman D, Qin R, Abyzov A, Ruddy K, Banck M, Lavoie Smith E, Dorsey S, Aaronson N, Sloan J, Loprinzi C, Beutler A. Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials. Supportive Care In Cancer 2017, 25: 3537-3544. PMID: 28634656, PMCID: PMC5693734, DOI: 10.1007/s00520-017-3780-y.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyCTCAE gradePatient-reported outcomesQLQ-CIPN20Peripheral neuropathyClinical trialsNCI Common Terminology CriteriaCommon Terminology CriteriaMultivariable linear mixed modelsRecent clinical trialsTerminology CriteriaAdverse eventsCancer QualityClinical caveatsSerial assessmentClinical trial datasetPractice guidelinesIndividual patientsEuropean OrganizationCTCAEPatientsOutcome variablesStrong positive associationLinear mixed modelsNeuropathy